stockchase picture

Compiling comments that experts make about stocks while on public TV.

There is 1 registered member and 142 guests viewing this site

Company Index

List by Company Name

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

List by Symbol

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Abbott Labs

Stock Symbol: ABT-N

Last Price Recorded: 37.7200 on 2013-05-23 01:14:01

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Date Signal Expert Opinion Price
2010-07-26 TOP PICK Christine Poole Diversified healthcare in the US. Have a branded pharmaceutical business providing drugs for arthritis, cholesterol and prostate cancer. Also had a nutritional business providing babies formula and adults’ nutrition. Also have stents, which is doing quite well globally. Trading at about 10.5X forward earnings. About 3.6% yield and have increased dividends on a regular basis.
 Price:
$49.240
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2010-05-27 DON'T BUY Brian Acker, CA The model price is $48.13, a 2% upside only. Fully priced.
 Price:
$47.870
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
No
2010-05-12 BUY Gordon Reid Have a little less than 50% of their business in pharmaceuticals. Their big drug is Humera for rheumatoid arthritis and doesn't come off patent until 2016. Also have about 20%-25% revenues from their nutritional business.
 Price:
$49.150
Subject:
US EQUITIES
Bias:
SELECTIVE
Owned:
Unknown
2010-04-26 TOP PICK Christine Poole Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
Price:
$50.370
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2010-04-14 BUY Don Lato Great company with a great pipeline. Humira, a rheumatoid arthritis drug, is their major product is on patent until 2016. Have never had a down year in stock price since 1992.
 Price:
$52.310
Subject:
NORTH AMERICAN
Bias:
CAUTIOUSLY OPTIMISTIC
Owned:
Yes
2010-01-14 COMMENT David Baskin Not hot on pharmaceuticals because of generic manufacturing and litigation risks. This one is a pretty good choice in pharmaceuticals with a pretty good product line up going forward. A lower risk way to play pharmaceuticals is through Johnson & Johnson (JNJ-N) that has both pharmaceuticals and branded consumer products.
 Price:
$55.350
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Unknown
2010-01-13 TOP PICK Gordon Reid Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
 Price:
$55.290
Subject:
US EQUITIES
Bias:
BULLISH on HEALTH CARE
Owned:
Yes
2009-07-08 BUY Gordon Reid Medical company, pharma and diagnostics. Good solid holding. Pays a good dividend. Good core holding for a portfolio.
 Price:
$46.310
Subject:
US EQUITIES
Bias:
CAUTIOUSLY OPTIMISTIC
Owned:
No
2008-11-21 TOP PICK Walter Gerasimowicz Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
 Price:
$51.520
Subject:
US & GLOBAL LARGE CAP
Bias:
UNKNOWN
Owned:
Yes
2007-08-29 BUY Norman Levine In the healthcare area this is an attractive name. Have medical devices, nutrition products and pharmaceuticals. Had troubles a few years ago but has gotten its act together.
 Price:
$51.490
Subject:
NORTH AMERICAN - LARGE
Bias:
DEFENSIVE
Owned:
Unknown
2005-08-25 DON'T BUY David Burrows Pharmaceuticals is a group that has underperformed for about 3 years. This one, in relation to the rest of the group, has peformed better althoough all of them are retracing over the last couple of months. Prefers the bioceutical companies.
 Price:
$45.110
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
No
2004-05-21 TOP PICK Harvey Eisen Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story.
 Price:
$40.000
Subject:
NOT APPLICABLE
Bias:
OPTIMISTIC
Owned:
Yes
2004-04-30 BUY David King Attractive. Continuing turnaround in their diagnostic business as well as a better pipeline than some of the other chief pharmaceuticals.
 Price:
$44.020
Subject:
NOT APPLICABLE
Bias:
OPTIMISTIC
Owned:
Unknown
2003-09-03 BUY Brad Willock Spinning off their hospital products division. A good strategy as there is not much growth. Not too expensive.
 Price:
$41.750
Subject:
US LARGE
Bias:
CAUTIOUS
Owned:
Unknown
2001-12-10 BUY David Burrows Pharmaceuticals may be re-establishing themselves for market leadership. Prefers Lily and Abbot
 Price:
$55.500
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUSLY OPTIMISTIC
Owned:
Unknown
Showing 46 to 60 of 61 entries

No Comments.

You must be logged in to comment.